Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Equity (2016 - 2025)

Ocular Therapeutix has reported Return on Equity over the past 12 years, most recently at 0.58% for Q4 2025.

  • Quarterly results put Return on Equity at 0.58% for Q4 2025, down 8.0% from a year ago — trailing twelve months through Dec 2025 was 0.58% (down 8.0% YoY), and the annual figure for FY2025 was 0.54%, up 27.0%.
  • Return on Equity for Q4 2025 was 0.58% at Ocular Therapeutix, up from 0.88% in the prior quarter.
  • Over the last five years, Return on Equity for OCUL hit a ceiling of 0.3% in Q2 2024 and a floor of 16.05% in Q3 2023.
  • Median Return on Equity over the past 5 years was 0.94% (2021), compared with a mean of 2.49%.
  • Peak annual rise in Return on Equity hit 12445bps in 2021, while the deepest fall reached -3296bps in 2021.
  • Ocular Therapeutix's Return on Equity stood at 0.97% in 2021, then plummeted by -115bps to 2.08% in 2022, then rose by 13bps to 1.81% in 2023, then skyrocketed by 73bps to 0.49% in 2024, then decreased by -17bps to 0.58% in 2025.
  • The last three reported values for Return on Equity were 0.58% (Q4 2025), 0.88% (Q3 2025), and 0.78% (Q2 2025) per Business Quant data.